Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBT (2016 - 2025)

OptimizeRx's EBT history spans 16 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, EBT rose 110.56% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.7 million, up 105.06%, while the annual FY2024 figure was -$19.4 million, 22.97% up from the prior year.
  • EBT for Q3 2025 was $1.0 million at OptimizeRx, down from $1.7 million in the prior quarter.
  • Across five years, EBT topped out at $2.2 million in Q4 2024 and bottomed at -$11.7 million in Q4 2023.
  • The 5-year median for EBT is -$3.3 million (2025), against an average of -$3.0 million.
  • The largest annual shift saw EBT crashed 8790.01% in 2022 before it soared 133.61% in 2025.
  • A 5-year view of EBT shows it stood at $623462.0 in 2021, then crashed by 152.26% to -$325836.0 in 2022, then tumbled by 3502.9% to -$11.7 million in 2023, then skyrocketed by 118.81% to $2.2 million in 2024, then crashed by 52.45% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's EBT are $1.0 million (Q3 2025), $1.7 million (Q2 2025), and -$3.3 million (Q1 2025).